Featured Opinions
The Weekly Pharma Merger Roundup
by Clifford M
As you all know by now, Merck announced on Monday that it will purchase Schering Plough for $41.1billion in a deal constructed as a reverse merger.
Remuneration Committees - Beware the Banking Backlash
by stadkins
The established pharma industry (by which I mean the profitable and sustainably cash generative companies) may appear to be less troubled than most industries by the fallout from the recession but one
Re-Importation - The killer of US pharma
by Anonymous (not verified)
The glorious days of high profit margins in the US are about to come falling down! Why?
Methicillin Resistant Staphylococcus aureus: A Growing Link between MRSA Infections and Pigs
by Clifford M
That methicillin resistant Staphylococcus aureus (MRSA) is in the news again is not surprising.
Mona Lisa - they will never be satisfied
No matter how many illness the industry helps to manage, payors and patients will never be satisfied. The industry have got mission impossible trying to keep Wall st, patients and payors happy.
The Merck-Schering Plough Deal: Why a Reverse Merger?
by Clifford M
Some of you may have been wondering why the $41.1 billion Merck-Schering Plough merger announced yesterday was designed as a reverse merger.
Investors to small biotech: we want our money back
Over the years in working in the health field I have always believed that if you develop good drugs and take care of patients that profits will naturally follow.
OK. Sales are down. What can you do?
by Steven Rosen
It's Q1 2009 and your sales are down, what can you do?
Manage Your Online Reputation Or I Will
I generally don't like to include threats as the title of my posts, but once again I thought it would be dramatic enough to get your attention.
The Merck-Schering Plough Deal: More Bad News for New Jersey
by Clifford M
Merck announced today that it was buying Schering Plough, the Kenilworth-New Jersey based drug maker, for $41.1 billion.
by Anonymous (not verified)
If you haven't already seen the news, Merck has announced it will buy Schering-Plough for $41.1 billion in cash and shares.
Connecting Scientists: What's Love Got to Do with It?
by Clifford M
Social media is the rage these days and, by all accounts, the things that are driving it popularity are making business connections, job hunting and the opportunity to meet/connect with others on a pe
Value based selling (VBS) is this a new form of bullshit bingo?
I am sure some of my smarter colleagues will enlighten me but surely this is more smokes and screen, is it not? What were we selling before small value, little value or no value?
Will the real Marketers stand up? - you are all sales men
Marketing and Marketers are weasel words, they have lost their meaning and to some extent their purpose. I am tired of living a lie, most Pharma Marketers are fake!
The public love the pharmaceutical industry, employees are proud of what they do and we are Wall st's favourite sector. Why?
Current Immigration Policies are Hurting American Science and Engineering
by Clifford M
For the past decade or so, I have worked as a career counselor at national scientific meetings where I present seminars about resume writing, interviewing techniques and other career related issues.
Having spent the morning listening to the speakers in the KAM track at the SFE Europe 2009 conference, a clear theme seems to be developing as an overarching message.
Christoph Schmidt (Actelion) answers your questions on 'Selling Pharmaceuticals In 2015'
At SFE Europe in Barcelona, yesterday's panel session, 'Selling Pharmaceuticals in 2015,'generated much interest from our delegates.
SFE Europe- the power of the text message
I am rather excited this afternoon.
I am lucky enough to be out in Barcelona at the moment, blogging and twittering from our 7th SFE Europe conference.
How to Avoid FDA Regulations Using Mobile Marketing
Based on my title, you're reading this for one of three reasons: 1) You sincerely are looking to skirt DDMAC rules and need some inspiration;